title: Immune modulation of collagen-induced arthritis by intranasal cytokine gene delivery: a model for the therapy of rheumatoid arthritis.
abstract: OBJECTIVE
  To develop a passively targeted, patient-compliant, intranasal interleukin-10 (IL-10) gene therapy delivery system and to investigate its therapeutic benefit in experimental collagen-induced arthritis, a model of rheumatoid arthritis.
  
  
  METHODS
  Arthritis was induced in DBA/1 mice and monitored following intranasal administration of an IL-10 plasmid (pG-IL-10) or the empty vector 2 days (days -2 and 19) prior to collagen injection (prophylactic group, as a single dose after collagen boost on day 21 (early therapy group, or as a single dose upon acquisition of a disease score of 3 (late therapy group. IL-10-induced alterations in cytokine secretion and proliferation by spleen and lymph node cells were assessed on days 31 and 65 and correlated with histologic changes and bone erosions assessed on day 65.
  
  
  RESULTS
  Intranasal delivery of pG-IL-10 significantly delayed arthritis onset and reduced disease severity in the prophylactic group and early therapy group, reduced cellular infiltration and bone loss in the early therapy group, and reduced T cell proliferation in response to collagen on days 31 and 65 in these two groups, with a significant reduction in tumor necrosis factor alpha production on day 65. Within the late therapy group, disease progression was arrested for the rest of the study. The intranasally administered pG-IL-10 targeted monocytes and macrophages and showed dissemination to inflamed joints and draining lymph nodes in vivo. Importantly, systemic levels of IL-10 (in serum) were transient (peaking on day 2) and undetectable by day 4.
  
  
  CONCLUSIONS
  Intranasal IL-10 gene delivery significantly reduces bone destruction, shows evidence of reducing joint inflammation, and may be mediated by high local levels of IL-10 produced by transfected monocytes trafficking to inflamed joints and draining lymph nodes.
authors.affiliation: King's College London School of Medicine at Guy's, St. Thomas' Hospital, London, UK.
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Woods
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Thompson
authors.forename: Paul H
authors.initials: PH
authors.lastname: Wooley
authors.forename: Gabriel
authors.initials: G
authors.lastname: Panayi
authors.forename: Linda S
authors.initials: LS
authors.lastname: Klavinskis
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D001169:Arthritis, Experimental / Q000276:immunology* / Q000628:therapy*; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000628:therapy; D002455:Cell Division / Q000276:immunology; D004195:Disease Models, Animal; D015316:Genetic Therapy / Q000379:methods*; D016753:Interleukin-10 / Q000235:genetics* / Q000276:immunology; D008214:Lymphocytes / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D012333:RNA, Messenger / Q000032:analysis; D012720:Severity of Illness Index; D013585:Synovitis / Q000276:immunology / Q000628:therapy; D019076:Transgenes; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology / Q000378:metabolism
chemical_list: D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10